zepbound or semaglutide vs. Wegovy: Differences Between Weight-Loss Medications Tirzepatide vs. Semaglutide for Weight

Cegla J, Troke RC, Jones B, Tharakan G, Kenkre J, McCullough KA, et al

Researchers actively study it for its targeted metabolic properties

Mukherjee, S., Ridgeway, A

Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 19 GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists Authors Abid M, Sheikh KS, Ahmad MS, Jiang H Received 19 January 2026 Accepted for publication 17 March 2026 Published 12 June 2026 Volume 2026:19 566414 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Donald McClain Mahroz Abid, 1 Khizer Sohail Sheikh, 1 Muhammad Shahbaz Ahmad, 2 Hongwei Jiang 1 1 Department of Metabolism and Endocrinology, Endocrine and Metabolic Disease Center, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Peoples Republic of China

The GLP-1 Cost Problem: Bigger Than Most Employers Realize GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound have reshaped the treatment landscape for both diabetes and obesity

How is ipamorelin different from HGH